First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-22

Study Completion Date

2021-04-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma

NCT00843037

Paraganglioma Pheochromocytoma

COMPLETED PHASE2

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

NCT00541008

Kidney Cancer

COMPLETED PHASE2

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

NCT01215578

Neuroendocrine Tumors Pancreatic Neoplasms Advanced Disease +1 more

TERMINATED PHASE2

Open-label Study of Surufatinib in Japanese Patients

NCT05077384

Neuroendocrine Tumors Non-hematologic Malignancy

COMPLETED PHASE1/PHASE2

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

NCT00499473

Adult Anaplastic Astrocytoma Adult Diffuse Astrocytoma Adult Giant Cell Glioblastoma +5 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing).

SECONDARY OBJECTIVES:

* To determine overall survival and progression free survival.
* To determine time to progression.
* To determine objective response rate at one year.
* To determine time to and duration of tumor response.
* To assess safety profile including a dedicated cardiovascular management (home-blood pressure monitoring, ECG and echocardiography).

EXPLORATORY OBJECTIVES:

-Identification of predictors of response as well as surrogate markers of overall survival is anticipated

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sunitinib

sunitinib 37.5 mg per day

Group Type EXPERIMENTAL

Sunitinib

Intervention Type DRUG

sunitinib 37.5 mg per day

Placebo

Placebo 37.5 mg per day

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo 37.5 mg per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sunitinib

sunitinib 37.5 mg per day

Intervention Type DRUG

Placebo

Placebo 37.5 mg per day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sutent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of malignant PPGL, based on imaging or biopsy evidence of metastases in liver, bones, lungs and or lymph nodes, combined with at least one of two further confirmatory diagnoses: 1. diagnosis of PPGL from histopathological review of resected or biopsied tissue performed by a skilled pathologist (centralized review will be performed in all cases either before enrolment in case of any doubt or during the study); or 2. in patients where tumor tissue is unavailable for formal pathological review, from combined biochemical and functional imaging evidence of PPGL (e.g., MIBG scintigraphy combined with consistently and highly elevated plasma or urine levels of metanephrines).
* Metastatic disease not amenable to surgical resection
* Pre-treated or not
* Whatever the genetic status (sporadic or inherited)
* Evaluable disease according to RECIST 1.1 criteria
* Progressing disease within 18 months at imaging prior to randomization according to RECIST. The recent scan indicating progression may be used as the screening scan if within 28 days of randomization
* ECOG performance status 0-2
* Life expectancy ≥ 6 months as prognosticated by the physician
* Age ≥18 years, no superior limit
* Adequate bone marrow reserve (Hb \> 8, neutrophils ≥ 1500/mm³ and platelets ≥80.000/mm³)
* Effective contraception in pre-menopausal female and male patients
* Negative pregnancy test
* Patient´s signed written informed consent
* Ability to comply with the protocol procedures
* Ability to take oral medication

Exclusion Criteria

* Large or small cell-poorly differentiated neuroendocrine carcinoma according to WHO 2000 classification
* History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years.
* Severe renal (GFR \<30ml/mn or nephrotic syndrome) or hepatic insufficiency (ALT / AST \> 2.5 x ULN or ALT/AST \>5 x ULN if liver function abnormalities are due to the underlying malignancy and/or total serum bilirubin \> 2.5 x ULN)
* Patients with cardiac events within the previous 12 months, such as myocardial infarction (including severe/unstable angina pectoris), coronary/peripheral artery bypass graft, revascularization procedure symptomatic congestive heart failure (CHF, ejection fraction \<45%), ), uncontrolled cardiac arrhythmia, clinically significant bradycardia, cerebrovascular accident or transient ischemic attack, or pulmonary embolism
* Hypertension that cannot be controlled despite medications (\>=160/95 mmHg despite optimal medical therapy)
* Abnormal cardiac function with 12 lead ECG. Ongoing cardiac dysrhythmias of NCI CTC grade \>=2, atrial fibrillation of any grade, or prolongation of the QTc interval to \>470 msec for males or \>480 msec for females.
* Brain metastases (exception if stable and asymptomatic for more than 3 months)
* Pregnancy or breast feeding
* Previous treatment with the drug under study. Prior systemic treatment with any tyrosine kinase inhibitors or anti VEGF angiogenic inhibitors.
* Current treatment with another investigational drug.
* Treatment with potent CYP3A4 inhibitors and inducers within 7 and 12 days, respectively prior to study drug administration
* Concomitant treatment with therapeutic doses of anticoagulants. Low dose warfarin (Coumadin) up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed as well as heparin-based anticoagulation
* Prior treatments with chemotherapy, immunotherapy, somatostatine analog therapy drug , thoracic radiotherapy within 4 weeks prior to inclusion
* Major surgery for any cause or local radiotherapy within one month prior to visit 1
* Liver embolisation therapy within the last 3 months prior visit 1 except if progression is demonstrated and embolised lesion not used as targets
* Unrecovered toxicity from any kind of therapy
* Active or suspected acute or chronic uncontrolled disease that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No